Puma Biotechnology to Participate in a Panel Discussion at TD Cowen’s 44th Annual Health Care Conference
February 22 2024 - 4:10PM
Business Wire
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical
company, announced that Alan H. Auerbach, Chairman, Chief Executive
Officer, President and Founder of Puma, will attend TD Cowen’s 44th
Annual Health Care Conference, which will be held March 4 – 6,
2024, at the Boston Marriott Copley Place in Boston. Mr. Auerbach
will participate in a Breast & Lung Cancer Corporate Panel
Discussion on March 6 at 9:10 a.m. ET.
A live webcast of the Breast & Lung Cancer Corporate Panel
Discussion will be available at
https://wsw.com/webcast/cowen154/panel9/2257542, and a replay will
be available on Puma’s website for 30 days following the
presentation at
https://www.pumabiotechnology.com/ir_events.html.
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a
focus on the development and commercialization of innovative
products to enhance cancer care. Puma in-licensed the global
development and commercialization rights to PB272 (neratinib,
oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral
was approved by the U.S. Food and Drug Administration in 2017 for
the extended adjuvant treatment of adult patients with early stage
HER2-overexpressed/amplified breast cancer, following adjuvant
trastuzumab-based therapy, and is marketed in the United States as
NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also
approved by the FDA in combination with capecitabine for the
treatment of adult patients with advanced or metastatic
HER2-positive breast cancer who have received two or more prior
anti-HER2-based regimens in the metastatic setting. NERLYNX was
granted marketing authorization by the European Commission in 2018
for the extended adjuvant treatment of adult patients with early
stage hormone receptor-positive HER2-overexpressed/amplified breast
cancer and who are less than one year from completion of prior
adjuvant trastuzumab-based therapy. NERLYNX® is a registered
trademark of Puma Biotechnology, Inc.
In September 2022, Puma entered into an exclusive license
agreement for the development and commercialization of the
anti-cancer drug alisertib, a selective, small molecule, orally
administered inhibitor of aurora kinase A. Initially, Puma intends
to focus the development of alisertib on the treatment of small
cell lung cancer and breast cancer. In February 2024, Puma
initiated ALISCA-Lung 1, a Phase II clinical trial of alisertib
monotherapy for the treatment of patients with extensive stage
small cell lung cancer.
Further information about Puma Biotechnology may be found at
https://www.pumabiotechnology.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240222267179/en/
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc.,
+1 424 248 6500 info@pumabiotechnology.com
ir@pumabiotechnology.com
David Schull or Olipriya Das, Russo Partners, +1 212 845 4200
david.schull@russopartnersllc.com
olipriya.das@russopartnersllc.com
Puma Biotechnology (NASDAQ:PBYI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Puma Biotechnology (NASDAQ:PBYI)
Historical Stock Chart
From Apr 2023 to Apr 2024